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Abstract
KCNMA1 encodes the a-subunit of the large conductance, voltage and Ca2+-
activated and Voltage-dependent potassium channel (BKCa) and was shown by 
others and us to be a potential drug target gene in several cancers, including breast 
cancer. In addition, we studied the role of alternative pre-mRNA splicing events of 
KCNMA1 in migration, invasion, proliferation and dispersal of breast cancer cells. 
It is conceivable that by targeting gene variants we can attenuate processes such as 
distant metastasis and angiogenesis. Here we reviewed literature on the alternative 
splicing events specific to breast cancer metastasis to brain, its microenvironment, 
the biological activity of most alternatively spliced isoforms. We conclude that 
based on our and others’ work KCNMA1 and other such gene variants contribute 
to breast cancer dispersion, invasion, growth, and progression in the tumor micro-
environment. Thus KCNMA1/BKCa channels and their variants are opportunistic 
diagnostic, prognostic and treatment targets in breast cancer.
Keywords: KCNMA1 pre-mRNA splicing, BKCa channelopathy,  
breast cancer-dispersion, invasion, growth, angiogenesis, progression,  
treatment target
1. Introduction
1.1 Metastatic breast cancer etiology
Breast cancer is the most common type of cancer affecting women. Despite 
great advances in primary breast cancer treatment a significant number of women 
develop metastases in different organs of the body, especially brain [1], possibly as 
a result of the emergence of targeted and aggressive systemic cancer therapy. The 
actual incidence of brain metastases is not precisely known; however, studies sug-
gest that 6–16% of patients with metastatic breast cancer develop brain metastases 
during their lifetime. Furthermore, autopsy studies have reported brain metastases 
in 18–30% of patients dying of breast cancer [2]. The majority of women who 
develop brain metastases have undergone aggressive treatment for stage IV disease 
[3–5]. Although brain metastasis is the leading cause of breast cancer death, its 
pathogenesis is poorly understood and the predictors of breast metastasis to brain 
are yet to be characterized. Albeit recent studies found genes that mediate breast 
cancer metastasis to brain [6, 7]. Targeting metastatic breast cancer cells in brain is 
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extremely difficult as brain provides a “safe haven” for cancer cells. Gene expression 
profiling has been used to predict metastatic gene-expression signature that is pres-
ent in a subset of primary breast tumors [8]. However, a reliable profile has not yet 
been identified that specifically predicts brain metastases. Therefore, it is extremely 
important to study the genetic changes in breast cancer cells that metastasize to 
brain and develop specific targeted therapeutic molecular agents.
2. Channelopathy promote breast cancer metastasis
Cancer research is not only focusing on understanding the possible role of 
transmembrane-BKCa channels in cancer development and progression but also on 
development of BKCa channel modulator drugs to attenuate cancer growth. Several 
researchers, including us have shown that brain tumor cells express BKCa and ATP-
sensitive potassium (KATP) channels that are highly responsive to minute changes 
in intracellular Ca2+ and ATP levels. This allows the brain tumor cells to develop 
pseudopodia for migration through constricted spaces in the brain parenchyma, as 
depicted in Figure 1. Several articles have described the efficacy of BKCa channel-
inhibiting drugs or molecules in reducing tumors in preclinical mouse tumor 
models. A recent study has shown the role of intracellular BKCa channels (mitoBKCa) 
in cancer cell biology [9, 10].
2.1 Ion channels in breast cancer metastasis
Even now the metastatic breast cancers are incurable. Extensive research has 
shown that breast cancer metastasis to other organs, including brain is a compli-
cated process. It is widely believed that breast cancer cells escape the primary site 
Figure 1. 
Anticipated role of BKCa and KATP channels in breast cancer cells that seek brain and colonize in brain 
parenchyma. The potassium ion channels expressed in breast cancer cells are extremely sensitive to minute surge 
of extracellular and intracellular Ca2+ and cause K+ efflux through BKCa channels. Similarly, slight imbalance 
in ADP-ATP levels in the cell causes K+ efflux through KATP channels. Then the ion imbalance triggers the Ca
2+ 
entry, which promotes cancer cell migration though pseudopodia.
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and migrate by lymphatic route to lymph nodes and vascular route to colonize in 
other organs including brain [11, 12]. Gene-expression profiling studies of breast 
cancer cells indicate that specific molecular pathways are associated with dissemi-
nation of primary tumor cells through a vascular route and not by lymphatic dis-
semination [12]. There is much interest in studying how and when the cancer cells 
initiate the metastatic cascade so that a therapeutic intervention can be developed 
to stop or delay the metastasis. Some cancer researchers [13] believe that targeted 
treatment of breast cancer with ER/PR modulators (Aromatase inhibitors) and 
targeted biologics such as Herceptin (Her-2 neu inhibitor) [14] and bevacizumab 
[15] (anti-vascular). Others argue that the metastasis of cancer cells is triggered 
by a dysregulated cellular Ca2+ homeostasis and altered Ca2+ signaling caused 
by imbalanced fluxes through ion channels and transporters [10, 16]. The BKCa 
channels are more sensitive to Ca2+ ions in cancer cells. In this regard, we studied 
whether the increased sensitivity of potentially new BKCa channel variant protein 
encoded by splice variants (Figure 2) KCNMA1ΔE2 and KCNMA1vE22 to intra 
and extra cellular Ca2+ in breast cancer [17]. In fact, a recent evidence indicates that 
KCa-Ca2+ channel complexes were found in cancer cells and contribute to cancer-
associated functions such as cell proliferation, cell migration and the capacity to 
develop metastases [10]. The BKCa channels are unique since its activity is triggered 
by depolarization and enhanced by an increase in μM range of intracellular calcium 
[Ca2+i]. In this regard, we recently showed that BKCa channel variant encoded by 
a new splice variant KCNMA1vE22 is highly sensitive to [Ca2+i] and causes glioma 
progression to high grade glioblastoma multiforme (GBM) [18]. We also discovered 
a new splice variant KCNMA1vE22 in breast cancer cells that contributes to breast 
cancer metastasis to brain (to be published). Epigenetics play an important role in 
cancer initiation, growth and progression. Understanding the precise mechanism 
helps us in developing diagnosis, prognosis and treatment strategies for affected 
cancer patients. For example, overexpression of Ezh2 plays a role in many cancers, 
Figure 2. 
BKCa channel is a 7-transmembrane tetramer of four monomeric pore-forming alpha-subunits encoded by 
KCNMA1. The cytoplasmic C-terminal domain has RCK1 and RCK2 (with calcium bowl) segments. We 
identified KCNMA1ΔE2 and KCNMA1E22 in human brain-specific metastatic breast cancer cells. Using 
relevant siRNA designs, we showed that these splice variants are formed by the deletion of exon 2 (E2) and 108 
base pair deletion in exon 22 (E22), respectively.
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including breast cancer and brain tumors. H3K27M serves as an oncohistone and, if 
mutated it contributes to tumor development as Ezh2 is no longer able to methylate 
the histone and gene expression is aberrantly upregulated.
Furthermore, a recent computational analysis of human genomic sequence 
identified mutations that cause pathogenic splicing abnormalities in breast cancer 
susceptibility genes, BRCA1, BRCA2 and other genes [19]. Several investigations 
have reported that voltage gated ion channels are expressed in several cancers and 
contribute significantly to cell signaling, cell cycle progression and cell volume 
regulation, cancer cell proliferation, as well as metastasis. Hence, there is a great 
deal of interest in possible therapeutic potential of voltage gated ion channels as 
pharmacological targets [20, 21].
2.2 Metastatic breast cancer in brain microenvironment
Cancer cells have the innate ability to “exploit” the “chaotic” environmental chal-
lenges surrounding them and grow uninterrupted by manipulating transportome 
that regulate proliferation, apoptosis, metabolism, growth factor signaling, migra-
tion and invasion. Ion channels and transporters are some of the key modulators of 
cancer progression in hostile tumor microenvironment that includes hypoxia. It has 
been suggested that modulation of ion channels by the hypoxic environment may 
contribute to the aggressive phenotype observed in GBM cells residing in a hypoxic 
environment [22]. In hostile microenvironment such as hypoxia, BKCa channels 
are modulated to aid cancer cell invasion and neovascularization. Affymetrix 
Array analyses of brain tumor cell lines where KCNMA1 was either overexpressed 
or suppressed showed significant changes in genes involved in cell proliferation, 
angiogenesis, cell cycle, and invasion [18].
2.3 KCNMA1/BKCa channel splice variants in breast cancer
During the past decade, a number of genes associated with breast cancer have 
been cloned and identified. Gene expression levels alone cannot fully explain gene 
function as alternative splicing produce multiple mRNAs and protein isoforms. 
New molecular insights indicate that the metastatic capacity of breast tumors is 
an inherent feature, and not necessarily a late, acquired phenotype [23, 24]. Breast 
cancer cells show alternative mRNA splicing and have prognostic and therapeutic 
value [21]. Although there are many reports of alternative splicing events specific 
to breast cancer [25, 26], the biological activity of majority of alternatively spliced 
isoforms, and specifically their contribution to metastatic breast cancer biology, 
remains to be investigated. As many researchers are focusing on “Understanding 
and Preventing Brain Tumor Dispersal”, we recently reported on a novel KCNMA1 
mRNA splice variant with a deletion of 108 base pairs (KCNMA1v) mostly overex-
pressed in high-grade gliomas [18]. In order to understand the role of alternative 
pre-mRNA splicing events of KCNMA1/ BKCa channels, we employed specific 
inhibitors. We showed that the modulation of KCNMA1/BKCa channels in brain spe-
cific metastatic breast cancer cells (MDA-MB361) resulted in attenuation of migra-
tion, invasion [11, 17]. Further, we identified a hitherto unknown KCNMA1 variant 
KCNMA1vE22 (to be published) with a deletion of 108 base pairs of nucleotides and 
deletion of the entire exon-2 (KCNMA1ΔE2) expressed only in metastatic breast 
tumor cells seeking brain (Figure 2). However, biological function of KCNMA1ΔE2 
under different tumor microenvironment is yet to be elucidated. The KCNMA1 
splicing effects and the potential role of KCNMA1ΔE2 as a critical posttranscrip-
tional regulator of BKCa channel isoform resulting in diversified channel functions 
merit further investigation.
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Identifying the most optimal and novel biomarker(s) for breast cancer metastasis 
to brain is ideal [27, 28] yet challenging because of the multi-factorial nature of the 
disease. The roles of roles of different ion channels in the development of cancer 
have been reported [29]. The identification of a potential new biomarker has relied 
heavily on an increase or decrease in gene expression, but these changes may not 
always result in altered protein expression. Growing evidence indicates that alter-
native or aberrant pre-mRNA splicing resulting in protein isoforms with diverse 
functions occurs during the development, progression, and metastasis of breast 
cancer [29]. Earlier, we have reported that the BKCa channels play a role in human 
breast tumor progression, cell proliferation, invasion, and micro-metastases [11, 17]. 
Nevertheless, the precise role of KCNMA1 and its splice variants in modification of 
BKCa channel functions in promoting breast cancer metastasis to brain is still unclear. 
Therefore, to understand the role of BKCa channels in breast cancer metastasis to 
brain the we showed that the relative messenger RNA levels in MDA-MB-361 cells 
derived from human metastatic breast tumor in brain were higher than metastatic 
breast cancer cells (MDA-MB-231) that prefer other organs and primary breast can-
cer (MCF-7) cells. In addition, using GeneChip Exon array (Affymetrix) we probed 
the presence of alternative splicing of KCNMA1 in MDA-MB-361, MDA-MB-231 and 
MCF-7. The array data showed that KCNMA1 splicing pattern is different among cell 
lines with three different phenotypes (to be published).
The PCR results validated the findings of Exon array study. Two distinct splice 
variants expressed in breast cell line (MDA-MB-361) metastatic to brain were 
identified (i) deletion of exon 2 (KCNMA1ΔE2) between S0-S1 protein subunit 
(Figure 2) corresponding to the cytoplasmic potential domain of BKCa channel 
α-subunit and (ii) deletion of 108 bp in exon 22 (KCNMA1vE22) between the 
S9 and S10 protein subunit (C-terminus). However, the biological function of 
these alternative splice variants in breast cancer remains to be investigated. To our 
knowledge we believe that our laboratory is the first to report the presence of these 
variants in metastatic breast cancers. We established that KCNMA1vE22 plays a 
key role in several biological functions of MDA-MB-231BR cell line as represented 
in Table 1.
3. BKCa channels and neovascularization
Altered ion channels could play a pivotal role in physiological angiogenesis 
in including cancer [30, 31]. BKCa channel inhibitor modulated the tumorigenic 
ability of hormone-independent breast cancer cells via the Wnt pathway [32]. 









at the 5th 
week
Untransfected 1 ± 0.09 1 ± 0.10 1 ± 0.17 1 ± 0.11 1 ± 0.21
Vector-transfected 0.98 ± 0.04 1.01 ± 0.12 0.95 ± 0.13 1.2 ± 0.15 1 ± 0.27
KCNMA1vE22-
transfected
1.4 ± 0.12 1.9 ± 0.15 1.5 ± 0.19 1.6 ± 0.21 3.8 ± 0.42
Data shown are in SEM of n = 3 in triplicates. Biological function assays [11] and functional activity of BKCa 
channels were measured by membrane potential assay using FlexStation and in vivo mouse brain tumor models as 
described by us earlier.
Table 1. 
Effect of KCNMA1vE22 expression on biological functions of MDA-MB-231BR cell line.
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Our work shows an association between the BKCa channel isoform expression and 
VEGF secretion by breast tumor cells, which might be exacerbated under hypoxia 
that has implications for vascular permeability and anticancer drug delivery (to 
be published). Understanding the underlying mechanism and splicing patterns of 
KCNMA1 and expression of the splice variant KCNMA1ΔE2 under normoxia and 
hypoxia alone and in coculture with brain endothelial cells will shed light on the 
role of KCNMA1 alternative splicing in metastatic breast tumor biology. Perhaps the 
discovery and validation of brain specific metastasis-associated KCNMA1 alternate 
splice variants will serve as new tools for the diagnosis and classification of breast 
tumor patients with high risk of brain metastasis. In fact, splice variations in a num-
ber of genes have already been shown to correlate with malignancy and their occur-
rence could precede clinical cancer diagnosis [33]. To date, however brain-specific 
alternate KCNMA1 splice variants in breast cancer have not been reported. The 
variant KCNMA1ΔE2 that we have discovered potentially may fill the gap to serve as 
a biomarker of breast cancer metastasis to brain. Undoubtedly, the research on the 
putative association between KCNMA1 splice variants and breast cancer metastases 
to brain will prove to be an extremely productive exercise for the identification of 
a new generation of biomarkers. KCNAM1/BKCa channels are hypothesized to be 
involved in VEGF secretion and neovascularization in brain tumors. We tested this 
hypothesis by activation and suppression of KCNMA1 in brain tumor cells and 
constructed a potential VEGF signaling pathway adapted from KEGG VEGF signal-
ing pathway (Figure 3).
We rationalize that KCNMA1ΔE2 is expressed specifically in metastatic breast 
tumors in brain, and this requires validation to confirm its role as a potential 
transformation biomarker of breast cancer metastasis to brain. In metastatic breast 
tumor cells seeking brain there is an upregulation and constitutive activation 
of KCNMA1, which correlates with increased malignancy [11]. In this context, 
Figure 3. 
Adapted from KEGG-VEGF signaling pathway: we activated and suppressed KCNMA1 in brain tumor cells 
and constructed a probable VEGF signaling pathway affected by modified KCNAMA1 expression. The genes in 
rectangular boxes—red represents genes overexpressed by KCNMA1 overexpression and black represents genes 
downregulated by KCNMA1 inhibition in U-87 (glioma cells).
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we showed (Figure 4) that the KCNMA1 is overexpressed in breast cancer cells 
metastatic to brain (MDA-MB-361) and exhibit differences in expression levels in 
other non-metastatic (MCF-7) and metastatic to other organs (MDA-MB-231). 
MDA-MB-231 BR was established from the triple negative MDA-MB-231 cells, 
which are highly metastatic but have no organ specificity. The MDA-MB 231-BR cell 
line was derived from MDA-MB-231 cells following sequential rounds of implanta-
tion, resection from the brain, and re-injection into mice. Eventually a subline 
with selectivity for the brain was isolated [34], and exhibit higher KCNMA1 level 
than parental MDA-MB-231 cells, however the expression was far lower than the 
naturally-selected MDA-MB-361 cells (Figure 4).
In addition, alternate splicing of KCNMA1 [17] including KCNMA1ΔE2 
may provide a mechanism to generate a physiologically diverse complement of 
functionally and structurally diverse BKCa channel isoform that might affect cell 
proliferation, cell cycle, migration and micrometastases in brain. Future studies will 
validate the role of KCNMA1ΔE2 in brain-specific metastatic process. Inhibiting 
KCNMA1ΔE2 in in vitro and in vivo models with shRNA or the variant BKCa chan-
nel using specific inhibitor like Iberiotoxin to attenuate breast tumor metastasis to 
brain using human metastatic breast tumor xenograft mouse models will be very 
stimulating.
4. Discussion
4.1 Splicing in health and disease
Many human diseases are implicated to errors in mRNA splicing. These aber-
rant splicing also provides an opportunity to develop targeted treatment to correct 
the faulty gene in some genetic disorders, or target aberrant protein encoded by 
these gene variants in human cancers. Breast cancer-specific biomarkers might 
generate specific epitopes that offer targets for developing diagnostic, prognostic 
and immunotherapy [35]. Articles on alternative pre-mRNA splicing regulation 
in cancer [36] and misregulation of mRNA splicing in cancer [29] highlights the 
important roles in promoting aberrant splicing, which in turn contributes to all 
aspects of tumor biology.
Figure 4. 
BKCa channels in breast cancer biology-expression of KCNMA1 by qPCR (A) and alternate splice variants 
(B) using Affymetrix Genechip Exon Array in MCF-7 (non Mets), MDA-MB-231 (Mets) and MDA-MB-361 
(brain Mets) cell lines.
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4.2 BKCa channels as target to attenuate breast cancer metastasis
The BKCa channels are known to function as oncogenes in certain cancers. These 
channels besides being sensitive to [Ca2+i] are highly dependent on amounts of 
outward K+ currents, which modulate the transmembrane potential of a cell. The 
BKCa channels are overexpressed in many types of cancers via gene amplification, 
alternative splicing or increased protein half-life. A recent study showed that by 
inhibiting BKCa channels with Iberiotoxin in breast cancer cells, tumorigenicity was 
reduced by downregulation of β-catenin and (phospho)Akt and HER-2/neu protein 
levels [37]. Evidence presented above clearly show that over expression of wild type 
BKCa channels or the presence of BKCa channel variant support breast cancer metas-
tasis to brain. Understanding the mechanism of its action in brain metastasis will 
provide a unique opportunity to identify and differentiate between low grade breast 
cancers that are at high risk for metastasis from those at low risk for metastasis. 
This distinction would in turn allow for the appropriate and efficient application 
of effective diagnosis, prognosis and treatments while sparing patients with low 
risk for metastasis from the toxic side effects of chemotherapy. Activation of BKCa 
channels was shown to be a novel molecular pathway involved in zoledronic acid-
induced apoptosis of MDA-MB-231 cells in vitro [32]. Du et al. [8] showed that BKCa 
promotes growth and metastasis of prostate cancer through facilitating the coupling 
between αvβ3 integrin and FAK. BKCa channels are shown to support cancer cell 
migration, invasion and tumorigenesis [11, 17, 18]. Hence it is extremely interesting 
to explore BKCa channels as putative targets for anti-breast cancer therapies.
4.3 Alternate splicing of BKCa channels in diagnosis and prognosis
Several articles have highlighted the use of alternative splicing as a promising 
source for new diagnostic, prognostic, predictive, and therapeutic tools [38–40]. 
The diversity of RNA species detected through RNA-seq holds the potential of 
extracellular RNAs as non-invasive diagnostic indicators of disease [41–44]. We 
recently reported that targeting the KCNMA1 variants may be a clinically beneficial 
strategy to prevent or at least slow down glioma transformation to GBM [18]. In 
both human and mouse lymphoma models, researchers have shown that MYC 
directly induced the transcription of genes encoding core splicing machinery 
components. They also showed that PRMT5 is involved in MYC-driven tumorigen-
esis in mice with lymphoma and discovered that tumor development was delayed 
[44]. Now due to high-throughput New Generation Sequencing (NGS) technologies 
the splicing diagnostic methodologies have improved. Hence NGS can be utilized 
in clinical diagnostics of splice variants in diagnosis, prognosis and treatment of 
breast cancers.
4.4 Perspective of KCNMA1 splice variants
We believe that future therapies for metastatic breast cancer depend on further 
investigation into the mechanisms and cellular events caused by oncogene splicing 
such as KCNMA1. Such studies should lead to the development of future therapies 
for this deadly type of cancer. KCNMA1 splice variants that are identified in breast 
tumor patients with brain metastasis will pave for accurate diagnosis and prognos-
tication. Furthermore, they provide potential targets for anticancer drug develop-
ment. Clinical outcome of KCNMA1vE22 expression in breast metastasis is expected 
to reveal the variants’ clinical importance. Quantifying the levels of KCNMA1vE22 
could be useful to identify biological process that increases the malignancy and 
affect prognosis of patients with breast cancer metastasis in the brain.
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5. Conclusions
Perhaps the discovery and validation of brain specific metastasis-associated 
KCNMA1 alternate splice variants will serve as new tools for the diagnosis and 
classification of breast tumor patients with high risk of brain metastasis. In fact, 
splice variations in a number of genes have already been shown to correlate with 
malignancy and their occurrence could precede clinical cancer diagnosis. To date, 
however brain-specific alternate KCNMA1 splice variants in breast cancer have not 
been reported. The variant KCNMA1ΔE2 and KCNMA1E22 that we have recently 
discovered potentially may fill the gap to serve as a biomarker of breast cancer 
metastasis to brain. Undoubtedly, the research on the putative association between 
KCNMA1 splice variants and breast cancer metastases to brain will prove to be an 
extremely productive research to identify new generation of biomarkers for early 
detection and therapeutic intervention in breast cancer patients with high risk for 
brain metastases.
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